A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
← catalyst calendarNCT07540910 · readout ≤ 103 d
Sponsored by Enanta Pharmaceuticals, Inc (industry) · ENTA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
98estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-01 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Inducible Urticaria
- Chronic Spontaneous Urticaria
Interventions
- Drug: EDP-978
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFSafety measured by adverse events
measured Up to 8 Days in SAD Cohorts
Safety measured by adverse events
measured Up to 28 Days in MAD Cohorts
Permalink · ENTA's whole pipeline · Catalyst calendar · Every registered study · What changed